No evidence of QT prolongation with supratherapeutic doses of aleglitazar.

AbstractAleglitazar is a dual peroxisome proliferator–activated receptor (PPAR)-α/γ agonist in clinical development, designed to offer a balanced activation of PPAR-α and PPAR-γ. A phase 2 trial has demonstrated improvements in dyslipidemia and glycemic control and reduction of cardiovascular risk m